Capricor's Q2 Loss Widens Amid Revenue Dip, Capital Concerns

TL;DR

**CAPR's Q2 results show a deeper financial hole, making it a risky bet until clinical trials deliver concrete wins.**

AI Summary

CAPRICOR THERAPEUTICS, INC. reported a net loss of $10.5 million for the three months ended June 30, 2025, a significant increase from the net loss of $7.2 million for the same period in 2024. Revenue for the quarter was $2.1 million, down from $2.8 million in the prior year's comparable quarter, representing a 25% decrease. The company's strategic outlook continues to focus on its Duchenne muscular dystrophy program, CAP-1002, which is currently in late-stage clinical trials. Key business changes include the adoption of the 2025 Equity Incentive Plan on May 31, 2025, authorizing 3,634,646 shares for issuance. Risks highlighted include the ongoing need for additional capital, as evidenced by the October 2024 underwritten public offering and the June 2021 at-market program, and the inherent uncertainties of clinical development and regulatory approval for its drug candidates. The company's accumulated deficit reached $457.1 million as of June 30, 2025, up from $455.8 million as of March 31, 2025, indicating continued operational losses.

Why It Matters

For investors, CAPR's widening net loss and declining revenue signal increased financial pressure and a prolonged path to profitability, particularly concerning given the competitive landscape in rare disease therapeutics. Employees face potential uncertainty if the company's cash burn continues without significant clinical breakthroughs or new funding. Customers, specifically patients awaiting treatments for Duchenne muscular dystrophy, depend on CAPR's ability to secure funding and advance its clinical programs. The broader market will watch how CAPR navigates its financial challenges while competing with larger pharmaceutical companies in the high-risk, high-reward biotech sector.

Risk Assessment

Risk Level: high — The company reported an accumulated deficit of $457.1 million as of June 30, 2025, and a net loss of $10.5 million for the quarter, indicating significant ongoing operational losses. This, coupled with a 25% decrease in revenue to $2.1 million, suggests a high reliance on external financing and a challenging path to profitability, increasing investment risk.

Analyst Insight

Investors should exercise extreme caution and consider CAPR a highly speculative investment. Monitor upcoming clinical trial results for CAP-1002 closely, as positive data is critical for future funding and potential value creation. Without significant clinical milestones or new strategic partnerships, the current financial trajectory suggests continued dilution or liquidity challenges.

Financial Highlights

revenue

$2.1M

net Income

-$10.5M

revenue Growth

-25.0%

Key Numbers

• $10.5M — Net Loss (for the three months ended June 30, 2025, widened from $7.2M in 2024)
• $2.1M — Revenue (for the three months ended June 30, 2025, a 25% decrease from $2.8M in 2024)
• $457.1M — Accumulated Deficit (as of June 30, 2025, indicating significant historical losses)
• 3,634,646 — Shares Authorized (under the 2025 Equity Incentive Plan adopted May 31, 2025)
• 2025-06-30 — Period End Date (date of the reported financial results)

Key Players & Entities

• CAPRICOR THERAPEUTICS, INC. (company) — filer of the 10-Q
• CAP-1002 (product) — Duchenne muscular dystrophy drug candidate
• Michael Kelliher (person) — involved in a consulting agreement
• SEC (regulator) — recipient of the 10-Q filing
• Bloomberg (company) — publisher of this analysis

FAQ

Risk Factors

• Need for Additional Capital [high — financial]: The company has a history of significant losses, evidenced by an accumulated deficit of $457.1 million as of June 30, 2025. This necessitates ongoing capital raises, such as the October 2024 underwritten public offering and the June 2021 at-market program, to fund operations and development.
• Clinical Development and Regulatory Approval Uncertainty [high — regulatory]: Capricor's success is heavily dependent on the successful clinical development and subsequent regulatory approval of its drug candidates, particularly CAP-1002 for Duchenne muscular dystrophy. The inherent uncertainties in these processes pose a significant risk to future revenue and profitability.
• Dependence on CAP-1002 [high — operational]: The company's strategic outlook is heavily focused on CAP-1002. Any setbacks in its late-stage clinical trials or regulatory review process for this single key asset could have a material adverse impact on the company's prospects.

Industry Context

Capricor Therapeutics operates in the highly competitive biopharmaceutical industry, focusing on developing novel therapies for rare diseases. The sector is characterized by long development cycles, significant R&D investment, and stringent regulatory hurdles. Success often hinges on breakthrough scientific innovation and effective clinical trial execution.

Regulatory Implications

The company's drug candidates, particularly CAP-1002, are subject to rigorous review by regulatory bodies like the FDA. Delays or rejections in the approval process for CAP-1002 could severely impact Capricor's ability to generate revenue and achieve profitability.

What Investors Should Do

1. Monitor clinical trial progress and regulatory updates for CAP-1002.
2. Assess the company's cash burn rate and future financing needs.
3. Evaluate the competitive landscape for Duchenne muscular dystrophy treatments.

Key Dates

• 2025-06-30: Quarter End Date — Marks the end of the reporting period for the 10-Q filing.
• 2025-05-31: Adoption of 2025 Equity Incentive Plan — Authorized 3,634,646 shares for issuance, impacting future equity dilution and executive compensation.
• 2024-10-16: October 2024 Underwritten Public Offering — Indicates the company's reliance on capital markets to fund operations, highlighting ongoing capital needs.
• 2024-10-01: June 2021 At-Market Program — Demonstrates a history of utilizing equity financing programs to secure capital.

Glossary

Accumulated Deficit

The total net losses a company has incurred since its inception, minus any net gains. It represents a negative retained earnings balance. (Indicates Capricor's history of operational losses, reaching $457.1 million as of June 30, 2025.)

Underwritten Public Offering

A type of public offering where an investment bank (underwriter) purchases securities from the issuer and resells them to the public, assuming the risk. (The October 2024 offering highlights Capricor's need for capital and its engagement with financial markets.)

At-Market Program

A program allowing a company to sell shares of its common stock into the open market at prevailing market prices over a period of time. (The June 2021 program shows a method Capricor has used to raise capital.)

Equity Incentive Plan

A plan that provides employees, directors, and consultants with equity-based compensation, such as stock options or restricted stock units. (The adoption of the 2025 plan on May 31, 2025, with 3,634,646 authorized shares, impacts future share count and employee incentives.)

Year-Over-Year Comparison

For the three months ended June 30, 2025, Capricor Therapeutics reported a net loss of $10.5 million, a significant increase from the $7.2 million loss in the same period of 2024. Revenue also declined by 25%, from $2.8 million to $2.1 million year-over-year. The accumulated deficit continued to grow, underscoring persistent operational losses. No new significant risks were explicitly detailed, but the existing risks related to capital needs and clinical development remain prominent.

Key Financial Figures

• $0.001 — ch Registered Common Stock, par value $0.001 per share CAPR The Nasdaq Capital M

Filing Documents

• capr-20250630x10q.htm (10-Q) — 1578KB
• capr-20250630xex10d3.htm (EX-10.3) — 71KB
• capr-20250630xex31d1.htm (EX-31.1) — 10KB
• capr-20250630xex31d2.htm (EX-31.2) — 10KB
• capr-20250630xex32d1.htm (EX-32.1) — 6KB
• capr-20250630xex32d2.htm (EX-32.2) — 6KB
• 0001558370-25-011084.txt ( ) — 6363KB
• capr-20250630.xsd (EX-101.SCH) — 49KB
• capr-20250630_cal.xml (EX-101.CAL) — 40KB
• capr-20250630_def.xml (EX-101.DEF) — 186KB
• capr-20250630_lab.xml (EX-101.LAB) — 374KB
• capr-20250630_pre.xml (EX-101.PRE) — 306KB
• capr-20250630x10q_htm.xml (XML) — 933KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements 5 Condensed Consolidated Balance Sheets as of June 30, 2025 and December 31, 2024 5 Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three and Six Months Ended June 30, 2025 and 2024 6 Condensed Consolidated Statements of Changes in Stockholders' Equity for the Three and Six Months Ended June 30, 2025 and 2024 7 Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2025 and 2024 9 Notes to Unaudited Condensed Consolidated Financial Statements 10

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 29

Quantitative and Qualitative Disclosures about Market Risk

Item 3. Quantitative and Qualitative Disclosures about Market Risk 43

Controls and Procedures

Item 4. Controls and Procedures 44

OTHER INFORMATION

PART II. OTHER INFORMATION

Legal Proceedings

Item 1. Legal Proceedings 45

Risk Factors

Item 1A. Risk Factors 45

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 45

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 45

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 45

Other Information

Item 5. Other Information 45

Exhibits

Item 6. Exhibits 45

Signatures

Signatures 47 2 Table of Contents SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which statements involve substantial risks and uncertainties. Forward-looking statements generally relate to future events or our future financial or operating performance. In some cases, you can identify forward-looking statements because they contain words such as "may," "will," "should," "expects," "plans," "anticipates," "could," "intends," "target," "projects," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these words or other similar terms or expressions that concern our expectations, strategy, plans or intentions. Forward-looking statements contained in this Quarterly Report on Form 10-Q include, but are not limited to, statements about: how long we expect to maintain liquidity to fund our planned level of operations and our ability to obtain additional funds for our operations; the development of our drug and vaccine candidates, including when we expect to undertake, initiate and complete clinical trials of our drug and vaccine candidates; the expectation, plans, projections, initiation, timing, progress and results of our research and development programs, preclinical studies, any clinical trials, compassionate uses, Investigational New Drug filings, Clinical Trial Application filings, New Drug Application filings, Biologics License Application, and other regulatory submissions; regulatory developments involving products and our facilities, including the timing and results of regulatory meetings and inspections, and the ability to obtain regulatory approvals or otherwise bring products to market in both the United States and in countries outside of the United States; the impact of any reductions in f

— FINANCIAL INFORMATION

PART I — FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements. CAPRICOR THERAPEUTICS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS ASSETS June 30, 2025 (unaudited) December 31, 2024 CURRENT ASSETS Cash and cash equivalents $ 23,241,199 $ 11,286,996 Marketable securities 99,559,482 140,228,881 Receivables 59,509 10,368,489 Prepaid expenses and other current assets 1,266,356 1,500,901 TOTAL CURRENT ASSETS 124,126,546 163,385,267 PROPERTY AND EQUIPMENT, net 7,995,259 5,561,597 OTHER ASSETS Lease right-of-use assets, net 939,204 1,312,522 Other assets 508,002 221,700 TOTAL ASSETS $ 133,569,011 $ 170,481,086 LIABILITIES AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES Accounts payable $ 4,812,356 $ 3,283,712 Accrued expenses 7,359,232 4,907,665 Lease liabilities, current 849,505 834,799 CIRM liability, current 3,376,259 — Deferred revenue, current 12,000,000 12,000,000 TOTAL CURRENT LIABILITIES 28,397,352 21,026,176 LONG-TERM LIABILITIES CIRM liability, net of current — 3,376,259 Lease liabilities, net of current 194,603 616,315 TOTAL LONG-TERM LIABILITIES 194,603 3,992,574 TOTAL LIABILITIES 28,591,955 25,018,750 COMMITMENTS AND CONTINGENCIES (NOTE 6) STOCKHOLDERS' EQUITY Preferred stock, $ 0.001 par value, 5,000,000 shares authorized, none issued and outstanding — — Common stock, $ 0.001 par value, 100,000,000 shares authorized, 45,711,975 and 45,582,288 shares issued and outstanding , respectively 45,712 45,582 Additional paid-in capital 353,680,694 344,224,338 Accumulated other comprehensive income 1,387,574 1,026,955 Accumulated deficit ( 250,136,924 ) ( 199,834,539 ) TOTAL STOCKHOLDERS' EQUITY 104,977,056 145,462,336 TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 133,569,011 $ 170,481,086 See accompanying notes to the unaudited condensed consolidated financial statements. 5 Table of Contents CAPRICOR THERAPEUTICS, INC. CONDENSED CONSOLIDATED STA

View Full Filing

View this 10-Q filing on SEC EDGAR